Tyra Biosciences Plunged 30% on a Number That Wasn't the One Being Tested

TYRA opened Wednesday down roughly a third, tagging a 10-month low near $18 before clawing back to close around $22 — still down about 18% on the session. The trigger was a single line in a Phase 2 report on its lead drug, dabogratinib: a 57% complete response rate at three months, below the 70% bar several analysts, including Piper Sandler and H.C. Wainwright, had flagged as the line between success and failure. For a pre-revenue biotech whose entire enterprise value rides on this one molecule, the stock had already run up about 13% in the week into the readout, and it closed still well off its $40.65 52-week high.

The obvious read is that the drug underperformed and the market cut its marks. That read is half right, and the half that's wrong matters more than the sell-off.

A dose-finding study, not a verdict

The number that broke the stock came from a cohort that was never meant to be a verdict. SURF302 is a Phase 2 dose-finding trial of oral dabogratinib — an FGFR3-selective inhibitor — in patients with FGFR3-altered low-grade intermediate-risk bladder cancer (NMIBC). The population it enrolled was deliberately mixed: some patients had a single tumor marker lesion, others had several. The 57% three-month complete response and the 79% overall response (11 of 14) are the aggregate of that combined 60 mg once-daily group. The market treated that aggregate as the answer to a question the study was only partly asking.

Here is the turn. The company's own plan is a Phase 3 in the adjuvant setting — given after the tumor is fully removed, when nothing is left behind. The Chief Medical Officer explicitly framed the single-marker patients as the group that "closely mirror[s] the adjuvant setting." And that is the subgroup the market did not price. In the single-marker patients, dabogratinib produced a 100% overall response rate (8 of 8), a 63% complete response at three months, and a 75% best-overall complete response. The 57% headline is dragged down by the multiple-marker patients, a higher tumor burden that is a different treatment setting entirely — the "ablative" one, for which Tyra is already planning a higher 70 mg dose cohort.

The safety story reinforces the same point. At 60 mg there were no Grade 3 treatment-related events, no Grade 4 or 5, no dose reductions, and no treatment-related discontinuations. Critically, there was no hyperphosphatemia, nail, or ocular toxicity — the three signatures that have dogged erdafitinib, the only FDA-approved FGFR inhibitor, and confined it to advanced disease. The thing this drug is being sold on is being an oral, first-line option in a disease where current care means repeated catheterization; a clean chronic-dosing profile is what makes that pitch credible, and the data supported it.

Eight patients is a coin flip

So why the sell-off, if the number that maps to the actual Phase 3 cleared the bar? Because the sample that cleared it is eight people. The single-marker subgroup is too small to distinguish a real 70% signal from noise. The primary endpoint, as the study actually reported it, was the 57% aggregate — and that is the number a regulator and a skeptical investor look at first. The company is proceeding to Phase 3, which is the difference between a failure and an ambiguity, but "proceeding" on the strength of an 8-patient subgroup is not the same as the data having proven out.

The exposure-response data cuts both ways, which is why the trade was so fast. Patients with drug levels above a set threshold responded at 86% versus 58% below it — evidence the mechanism works and that exposure drives the outcome. But it also shows up mostly in the multiple-marker, higher-burden patients, which is exactly the population that argues you may need the higher 70 mg dose, not the clean 60 mg registrational story the market wanted. That tension — the drug works, but maybe not at the neat single dose — is what turned a "positive" print into a "complicated" one.

None of this was a safety event. What priced was de-risking a crowded, over-extended position ahead of a binary catalyst, plus a below-threshold headline, plus trial-design uncertainty. That is a sentiment and expectation reset, not a business-model break.

Funded through the test

The second, more important fact is the balance sheet, and it is the part of the story that has the least to do with sentiment. Tyra ended June 30 with $353.9 million in cash, cash equivalents, and marketable securities against no meaningful debt, and management says that funds operations into the second half of 2028. The company loses money to get here — the second-quarter loss was $45.6 million — but it does not need to sell shares at $18 to reach the Phase 3. That matters because there is no earnings multiple to anchor on and no margin to defend; the entire value is the probability you assign to the adjuvant Phase 3, and a funded runway is what lets that bet survive on its own terms instead of being forced by the cash flow. The one overhang: the company expanded its at-the-market equity capacity from $150 million to $250 million, a standing invitation to dilute whenever the stock drifts.

There is a second, independent data point that does not depend on bladder cancer at all: the achondroplasia program (BEACH301), where the same molecule is being tested in children, with a safety-sentinel readout now expected in the first quarter of 2027. It was pushed back from earlier, which is why it deserves a qualifier — but if it lands, it is a second proof that the FGFR3 biology is real, decoupled from the NMIBC sample-size problem.

What actually resolves it

The stock will not settle on the September data; it will settle on the next two. First, the 70 mg cohort: if higher exposure lifts the multiple-marker responses without adding toxicity, the "wrong dose, not wrong drug" reading wins. Second, the feedback from health authorities on the Phase 3 adjuvant design — the design is the endpoint, and a clean design agreement is a re-rating event regardless of the 8-patient print. Neither has happened yet, and both are the defined conditions under which this stock re-prices in either direction.

The honest read is that the market may have graded the wrong denominator, but the sample is too small to call the right one. This is not a fallen stock you buy because the multiple is cheap — there is no multiple — and it is not a broken drug. It is a funded company holding a coin flip on an 8-patient subgroup, with the flip resolved by a 70 mg cohort and an FDA design conversation that have not yet taken place. Until those land, the 57% and the 75% are two readings of the same thin data, and the price reflects that the market is not yet sure which one it is grading on.